Objective: Chronic, low-level inflammation is associated with symptomatic bipolar disorder (BD) and with chronic insomnia. Disrupted sleep is a feature of episodes of both mania and depression. We examined the effect of neopterin, a marker of cellular immune activation, and kynurenine (KYN), an inflammatory byproduct of the serotonin pathway, on the association between total sleep time and depression severity in BD.
sleep abnormalities. [6] [7] [8] Activation of the kynurenine (KYN) pathway has been supported in a number of psychiatric disorders, including BD 9, 10 .While many studies have independently explored sleep, [11] [12] [13] inflammation, 7, 14 and the KYN 9,15 pathway in BD, there is increasing evidence that inflammation is an important factor in mood, stress, and sleep disturbance 16, 17 and needs to be examined simultaneously for a better understanding of the underlying biological mechanisms.
Additionally, there is a dearth of research exploring inflammation, metabolites of the KYN pathway, or sleep in acutely ill BD patients.
4
Mood spectrum disorders (BD, recurrent depressive disorder, and seasonal affective disorder) are accompanied by sleep dysregulations that are particularly common among bipolar participants. 8, 12, 13, 18 Sleep dysregulations in mood disorders commonly occur in acute manic or depressive states but are also prevalent during remission. 8, [19] [20] [21] A metaanalysis focusing on sleep in remitted BD participants highlights disturbances in several sleep parameters: longer sleep latency, longer sleep duration, and poorer sleep efficiency. 21 Sleep is a remarkably sensitive, but not specific, indicator of distress, and dysregulated sleep can occur for a variety of reasons. Inflammation has been shown to be associated with sleep disturbance and objective short sleep in primary insomnia and obstructive sleep apnea, and may mediate the association between sleep apnea and adeposity. [22] [23] [24] By examining the association of sleep dysregulation with inflammatory biomarkers in BD, we may gain an understanding of the sleep, mood, and inflammation connection.
The essential amino acid tryptophan (TRP) is a substrate for two important biosynthetic pathways: the serotonin (5-hydroxytryptamine of this diversion of serotonin to KYN is neopterin, a catabolic product of guanosine triphosphate that is a marker of cellular immune system activation produced by macrophages upon stimulation by interferon-gamma. [25] [26] [27] [28] 
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In the current study, we investigated the relationship between markers of the KYN pathway, neopterin, sleep, and clinical symptoms in acutely ill BD participants. We were also interested in exploring biomarkers and sleep patterns after symptom remission, to determine whether these biomarkers were potentially state vs trait characteristics independent of mood state. We hypothesized that:
1.
Patients with acute BD would have significantly lower total TRP and a higher KYN/TRP ratio and neopterin levels than healthy controls (HC).
2.
The KYN/TRP ratio and neopterin would be associated with severity of depressive and manic symptoms in acutely symptomatic participants with BD.
3.
Sleep duration and biomarkers including kynurenine pathway metabolites (TRP, KYN/TRP) and the proinflammatory cytokine neopterin would be associated with depressive and manic symptom severity.
Finally, we were interested in whether these markers changed with symptom remission in asymptomatic patients, and explored differences in clinical symptoms, sleep, and biomarkers between baseline and follow up. Scores between 7 and 12 were mild, and above 12 were severe manic phenotypes. The body mass index (BMI) for each participant was calculated by measuring height and weight. Participants received usual clinical care and were discharged from the program. After discharge from the hospital or partial hospital program, participants were followed each week by telephone and assessed for clinical improvement. A return visit was scheduled to collect a second blood sample when the subject was asymptomatic, or after 3 months had elapsed.
F I G U R E 1

| Measures
Additional measures were collected but not used for this analysis.
Saunders et al 35 provided a more detailed report on the methods and results of analysis of fatty acid concentrations.
| Objective measure of total sleep time
During the period of initial evaluation, participants wore an actigraph 
| Sample collection and biochemical analysis
Participants fasted for at least 6 hours, and blood was drawn in va- participants. This was the result of an inability to maintain regular contact with some participants owing to a number of issues (e.g., unstable
housing conditions). The maximum number of days to follow-up was 187; the median was 22 days and the average was 52 days. However, an analysis of dropouts vs those who continued to be a part of the study did not show any significant differences based on baseline clinical symptoms and demographics, including age and gender (P values >.16). Dependent variables were compared between BD smokers and nonsmokers using independent t tests. 
| RESULTS
| Demographic and clinical description of the sample
| Sleep and inflammation variables
The HC group slept an average of 6.9 hours a night, with a standard deviation of about 1 hour; and the mean lag (variability in bedtime from night to night) was 4 minutes, with a standard deviation of 1 hour. The BD group slept an average of 6.5 hours, with a standard deviation of almost 2 hours, and the mean lag was 23 minutes, with a standard deviation of 60 minutes. Total sleep time was correlated positively with depressive symptom severity and negatively with the severity of manic symptoms (Table 2) .
| Group comparisons of TRP, KYN/TRP, and neopterin
As hypothesized, the BD group had significantly lower levels of TRP than the HC group (P < .03) ( Table 1 ). The BD group did not differ significantly from the HC group in mean levels of KYN, KYN/TRP, and neopterin (Table 1) . (Table 3) .
| TRP
| Association of biomarkers and sleep with depressive and manic severity
The association of depressive severity was tested with four hierarchical regression models, using depressive severity as the dependent variable and total sleep time, KYN, TRP, and KYN/TRP as the predictor variables controlling for BMI (Table 4 ). Depressive severity was T A B L E 1 Demographics, clinical symptoms, and differences in sleep and biomarkers between healthy controls and bipolar disorder individuals significantly associated with KYN (model 3) and TRP (model 4), when total sleep time and BMI were accounted for. Models 3 and 4 (Table 4) accounted for 71% and 60% of the variance, respectively. Model 1, consisting of KYN/TRP and total sleep time, trended toward significance, accounting for 60% of the variance (Table 4) . Although total sleep time was significantly associated with manic severity in all four models, only the KYN/TRP biomarker trended towards significance (Table 5) . This model explained 35% of the variance (Table 5 ).
| Follow-up data
Exploratory analysis of the follow-up data showed that although the BD participants reported significantly decreased clinical symptoms of depression and mania, 35 no significant differences were detected in total sleep time, TRP, KYN/TRP. Total sleep time appears to have increased at follow-up but was not significantly different from baseline scores. This may have been the result of the high variability in total sleep time score for BD participants (Table 6 ).
| DISCUSSION
The current study examined the relationship between objective markers of sleep and biomarkers of TRP metabolism and inflammation in a group of acutely symptomatic BD individuals. We found significantly lower levels of TRP in BD patients compared to HC. We also found that biomarkers, in conjunction with total sleep time, were associated positively with depressive severity and negatively with manic severity in BD patients.
Our first question addressed whether there were group differences between BD and HC in total sleep time, TRP, and KYN/TRP. Our finding of lower TRP levels in acutely symptomatic BD participants was concordant with several recent reports examining TRP levels in BD and schizophrenia 10, 39, 40 and the theory that decreased plasma TRP levels in BD participants may potentially lead to dysfunctional brain serotonin synthesis and release. TRP depletion studies 41, 42 provide a useful tool to examine the role and association of serotonin in different psychiatric disorders. Most of the TRP depletion studies have focused on unipolar depression owing to decreased serotonin as an underlying cause. For example, TRP depletion has been associated either with no effect 43 or with a slight but insignificant relapse of manic symptoms in fully recovered BD patients. No TRP depletion studies have been carried out in acutely manic BD patients. 39 The present study provides evidence for decreased TRP levels in a naturalistic occurrence of acute mood episodes. While experimental studies support the notion that decreased levels may be a precursor to a depressed mood state, in our study it was unclear whether the decreased TRP levels preceded or resulted from an acute mood state. Secondly, we asked if TRP, KYN/TRP, and neopterin were associated with severity of depressive and manic symptoms. We did not find levels of neopterin, an inflammatory marker, to be significantly different from those in HC, and they were not associated with depression or mania severity. However, neopterin levels were found to be associated positively with the KYN/TRP ratio, which replicated earlier studies investigating depression and chronic inflammation. 44, 45 Further mechanistic studies examining the role of neopterin in mood disorders are warranted. For example, one study 25 found that significantly higher levels of neopterin predicted poststroke depression in patients who had previously experienced a major depressive episode. Another crosssectional study found a positive association between MDD with a history of suicide attempt and KYN but no association with neopterin. Finally, we asked whether total sleep time, TRP, and KYN/TRP changed with symptom remission in asymptomatic BD patients.
Despite subjectively reported decreased clinical symptoms, no differences were detected in the biomarkers or total sleep time. One explanation could be the short follow-up time -perhaps these markers change on a slower time scale, or they may leave a long-term residual mark of the episode, indicating a change in physiology despite remission. [49] [50] [51] However, the results should be treated with caution owing to the small sample size of the study. Additionally, the patients were all receiving medication for an acute mood episode, which makes it difficult to parse the effects of medication. Further, in order to maximize statistical power, the study investigated only one sleep variable -total T A B L E 4 Association between depressive symptom severity and total sleep time and KYN/TRP ratio in bipolar disorder (controlling for BMI) (n = 21) sleep time. However, sleep is a complex phenomenon and consists of multiple aspects which are easily measured using actigraphic devices.
Based on the results of the present study, different sleep variables, along with inflammatory markers, warrant further investigation with a larger sample size. Another important methodological factor was the use of a structured hospitalized setting compared to a home environment. It may be argued that a hospitalized setting led to patients feeling more stressed than the HC; however, we argue that the patients were already in acute distress and unable to cope with their existing resources, leading to inpatient hospitalization. The structured setting of the hospital often relieves stress through learning basic skills and teaching patients to generalize those skills to real-world naturalistic settings. Kyn, kynurenine; Kyn/TrP, kynurenine/tryptophan ratio; Trp, tryptophan.
T A B L E 6 Paired sample t test comparing clinical symptoms of depression, mania, sleep, and inflammation variables at baseline and follow-up in bipolar disorder Data represents mean (SD)
